373 related articles for article (PubMed ID: 19153118)
1. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
[TBL] [Abstract][Full Text] [Related]
2. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline cardiotoxicity after breast cancer treatment.
Hershman DL; Shao T
Oncology (Williston Park); 2009 Mar; 23(3):227-34. PubMed ID: 19418823
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
[TBL] [Abstract][Full Text] [Related]
7. HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.
Vaitiekus D; Muckiene G; Vaitiekiene A; Sereikaite L; Inciuraite R; Insodaite R; Cepuliene D; Kupcinskas J; Ugenskiene R; Jurkevicius R; Juozaityte E
Cardiovasc Toxicol; 2021 Jan; 21(1):59-66. PubMed ID: 32748118
[TBL] [Abstract][Full Text] [Related]
8. Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer.
Guenancia C; Ladoire S; Ghiringelli F; Rochette L; Vergely C; Cottin Y
Arch Cardiovasc Dis; 2017 Feb; 110(2):69-71. PubMed ID: 28216265
[No Abstract] [Full Text] [Related]
9. Monitoring of anthracycline-induced cardiotoxicity.
Jannazzo A; Hoffman J; Lutz M
Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline cardiotoxicity.
Jones RL; Swanton C; Ewer MS
Expert Opin Drug Saf; 2006 Nov; 5(6):791-809. PubMed ID: 17044806
[TBL] [Abstract][Full Text] [Related]
11. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
[TBL] [Abstract][Full Text] [Related]
14. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
Guenancia C; Lefebvre A; Cardinale D; Yu AF; Ladoire S; Ghiringhelli F; Zeller M; Rochette L; Cottin Y; Vergely C
J Clin Oncol; 2016 Sep; 34(26):3157-65. PubMed ID: 27458291
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
van Dalen EC; van den Brug M; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
[TBL] [Abstract][Full Text] [Related]
16. [Cardiotoxicity of conservative treatment of solid tumors].
Sivak LA; Askol'skiĭ AV; Lial'kin SA; Klimanov MIu; Maĭdanevich NN; Kasap NV
Lik Sprava; 2011; (3-4):51-9. PubMed ID: 22416364
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis.
Mohamed AA; Elmancy LY; Abulola SM; Al-Qattan SA; Mohamed Ibrahim MI; Maayah ZH
Cardiovasc Toxicol; 2024 Jun; 24(6):563-575. PubMed ID: 38700665
[TBL] [Abstract][Full Text] [Related]
18. A historical perspective of anthracycline cardiotoxicity.
Ewer MS; Von Hoff DD; Benjamin RS
Heart Fail Clin; 2011 Jul; 7(3):363-72. PubMed ID: 21749888
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
20. [Cardiotoxicity of anthracyclines: mechanisms and pharmacologic targets for prevention].
Andrieu-Abadie N
Therapie; 2004; 59(1):121-6. PubMed ID: 15199678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]